UCB SA (UCB)

140.00 -2.25 (-1.58%)
Close EUR Disclaimer
Industry
Pharmaceuticals
Sector
Healthcare
Employees
8767
Equity Type
ORD
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Contact Information
Address
Brussels,1070 Belgium
Phone
32 2 559 99 99
Fax
32 2 559 99 00
Top Executives
Name
Age
Since
Title
Jan Berger 67 2019 Independent Director
Jean-Christophe Tellier 65 2014 CEO & Executive Director
Susan Gasser 69 2021 Independent Director
Cyril Janssen 53 2015 Director
Charles-Antoine Emmanuel T. Janssen 53 2012 Director
Ulf Arne Wiinberg 66 2016 Independent Director
Pierre L. Gurdjian 63 2016 Independent Director
Jonkheer Cédric van Rijckevorsel 54 2014 Director
Jonathan M. Peacock 66 2021 Independent Chair of the Board
Daniel Janssen 88 0000 Honorary Deputy Chairman
Gerhard N. Mayr 78 2005 Honorary Chairman
Georges Jacobs de Hagen 84 2005 Honorary Chairman
Diégo du Monceau de Bergendal 74 1984 Honorary Chairman
Karel Boone 81 2000 Honorary Chairman
Mark Eyskens 0 2005 Honorary Chairman
Dame Kay Davies 73 2014 Independent Director
Maelys Castella 58 2023 Independent Director
Guy Keutgen 0 1990 Honorary Director
Jean-Louis Vanherweghem 0 0000 Honorary Director
Gaëtan van de Werve 0 2006 Honorary Director
Jean-Pierre Kinet 71 2008 Honorary Director
Alice Dautry 74 2015 Honorary Director
Prince Lorenz 0 2001 Honorary Director
Peter J. Fellner 81 2005 Honorary Director
Alan John Blinken 0 0000 Honorary Director
Frederic Roch Doliveux 68 2005 Honorary Director
Arnoud de Pret Roose de Calesberg 80 2005 Honorary Director
Norman J. Ornstein 76 2008 Honorary Director
Thomas Fulton Wilson McKillop 81 2009 Honorary Director
Jean van Rijckevorsel 0 1992 Honorary Director
Rodolfo J. Savitzky 62 2024 Independent Director
Dolca Thomas 54 2024 Independent Director
Nefertiti Greene 53 2024 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles